Abbasali Mahammadali Balospura

Abbasali Mahammadali Balospura

Active Director Director DIN 09017667
DIN 09017667 First appointment Jan 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since Jan 2021
Shareholding value •••• Premium profile

About Abbasali Mahammadali Balospura

Data last updated:

Abbasali Mahammadali Balospura is a Director at Pyxus Pharmaceuticals Private Limited (since 2021), Designated Partner at Joinhub Pharma Llp (since 2021) and Designated Partner at Aliyan Pharmaceuticals Llp (since 2024), and holds 2 more current directorships. The companies operate in Pharma, Home Appliances and Healthcare. The 2 current companies with reported revenue have a combined latest revenue of ₹37.50 Cr; the largest is Pyxus Pharmaceuticals Private Limited at ₹24.91 Cr (FY 2025). Earlier, Abbasali Mahammadali Balospura was a Director at Emed Healthtech Private Limited (2021).

DIN 09017667
Primary Designation Director
Industry Pharma
First Appointment 01 Jan 2021
Oldest Company Age 8 yrs
Largest company Pyxus Pharmaceuticals Private Limited · ₹24.91 Cr (FY 2025)
Combined revenue ₹37.50 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Jan 20212018₹24.91 Cr (FY 2025)Active
Designated Partner19 Jan 20212020₹12.59 Cr (FY 2023)Active
Designated Partner28 Oct 20242022Active
Bhr5 Pharmaceuticals Private Limited U24290GJ2022PTC137143
Director02 Dec 20222022Active
Designated Partner19 Jul 20212019Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Emed Healthtech Private Limited U74999GJ2019PTC129758
Director01 Aug 20212019₹2.68 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Joinhub Pharma Llp
Joinhub Global Exports Llp
Pyxus Pharmaceuticals Private Limited
Bhr5 Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Abbasali Mahammadali Balospura

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Abbasali Mahammadali Balospura

Abbasali Mahammadali Balospura currently holds 5 directorships: Pyxus Pharmaceuticals Private Limited (Director, since 01 Jan 2021, revenue ₹24.91 Cr (FY 2025)); Joinhub Pharma Llp (Designated Partner, since 19 Jan 2021, revenue ₹12.59 Cr (FY 2023)); Aliyan Pharmaceuticals Llp (Designated Partner, since 28 Oct 2024); Bhr5 Pharmaceuticals Private Limited (Director, since 02 Dec 2022); Joinhub Global Exports Llp (Designated Partner, since 19 Jul 2021).

Abbasali Mahammadali Balospura was first appointed on 01 Jan 2021 as Director at Pyxus Pharmaceuticals Private Limited. The most recent appointment on record is 28 Oct 2024 at Aliyan Pharmaceuticals Llp.

The 2 current companies of Abbasali Mahammadali Balospura that report revenue have a combined latest revenue of ₹37.50 Cr: Pyxus Pharmaceuticals Private Limited ₹24.91 Cr (FY 2025); Joinhub Pharma Llp ₹12.59 Cr (FY 2023).

Abbasali Mahammadali Balospura held 1 earlier board appointment: Emed Healthtech Private Limited (Director, 01 Aug 2021 to 01 Dec 2021).

The current boards of Abbasali Mahammadali Balospura's companies include Aabid Ali (Pyxus Pharmaceuticals Private Limited), Ahemadabbas Gulamhaidar Balospura (Pyxus Pharmaceuticals Private Limited), Salam Waheed Ahjel (Pyxus Pharmaceuticals Private Limited), Sanket Vinodbhai Shah (Bhr5 Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available